T HE analgesic
effect of pentazocine in patients with acute myocardial infarction is well accepted. However, the hemodynamic effects of this drug remain controversial, particularly in patients with coronary heart disease. Several investigators have observed that the administration of pentazocine resulted in a marked rise in mean pulmonary arterial pressure. This increase was considered to be a result of impaired left ventricular function which occurred as a consequence of the increased peripheral vascular resistance caused by the drug.1),10), 14) In contrast, other investigators have observed that pentazocine promoted only a slight increase in pulmonary arterial pressure and no effect on left ventricular function.13))17)-19) In view of these conflicting reports and the obvious clinical importance of this problem, we investigated the hemodynamic effects of pentazocine under the conditions of our own coronary care unit.
METHODS
Hemodynamic studies were performed on 12 patients (11 males, 1 female). The mean age of the group was 65 years (range 52-76 years).
All patients had
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Received for publication May 12, 1978. 253 Jap. Heart J. May, 1979 suffered from myocardial infarction 8 to 48 hours (mean 39 hours) prior to the study. Myocardial infarction was diagnosed by the combination of history of chest pain, characteristic ECG changes and typical elevations of pertinent serum enzymes. The infarction was anterior in 4 cases and inferior in the remaining 8.
The clinical course was characterized by only slight to moderate left ventricular failure, no patient presented with cardiogenic shock or pulmonary edema. the DBAP/IVCP ratio. There was a small sub-group of patients who demonstrated an increase of mean pulmonary arterial pressure greater than 8mm Hg. This group did not differ from the total group regarding changes in systemic arterial pressure, peripheral vascular resistance, LVSWI, MSER, or DBAP/IVCP ratio (Table II) .
DISCUSSION
Our results confirm the findings of others7),16),19) that, in patients with acute myocardial infarction, the administration of 30mg of pentazocine resulted in no significant hemodynamic changes.
Other investigators have observed an increased pulmonary arterial pressure following the administration of pentazocine.1),10),14),17),19) They have considered this increase to be a primary effect on the pulmonary vasculature17), 19) or a secondary effect caused by an elevation of left ventricular filling pressure. The latter was thought to occur as a result of an increased afterload on the left ventricle.1),10), 14) Our data indicate that any elevation in pulmonary arterial pressure was inconsistent and, in considering the whole group of patients, was statistically insignificant.
Although we did not directly measure left ventricular pressure it was unlikely that left ventricular filling pressure was altered due to an afterload induced reduction in left ventricular function. There was no change in peripheral vascular resistance which had been observed by several authors.1),10), 12),13),15),16) In addition , pentazocine caused no alterations in the indirect measurements of left ventricular function, that is, LVSWI, MSER, or the DBAP/IVCP ratio.
In considering the potential constricting effects of pentazocine on the pulmonary resistance vessels, previous investigators have invoked the EulerLiljestrand reflex and the respiratory depressant effect of pentazocine9),11) Our data indicate little if any respiratory depression shown by the insignificant changes in arterial PO2, pCO2 and pH. Thus, in those patients who showed an increase in pulmonary arterial pressure it was likely a direct effect of pentazocine on the pulmonary resistance vessels.
